Orange, CT9 Active Studies

Advanced Solid Tumors Clinical Trials in Orange, CT

Find 9 actively recruiting advanced solid tumors clinical trials in Orange, CT. Connect with local research sites and explore new treatment options.

9
Active Trials
7
Sponsors
5,096
Enrolling

Recruiting Advanced Solid Tumors Studies in Orange

RecruitingOrange, CTNCT03486873

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this ex...

3,500 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingOrange, CTNCT03093116

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotre...

500 participants
Turning Point Therapeutics, Inc.
View Study Details
RecruitingOrange, CTNCT05410145

A Study of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

This is a first-in-human (FIH), multicenter, open-label, dose-escalation, and dose-expansion Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and prel...

442 participants
D3 Bio (Wuxi) Co., Ltd
View Study Details
RecruitingOrange, CTNCT06219941

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participant...

190 participants
AstraZeneca
View Study Details
RecruitingOrange, CTNCT04851119

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to tr...

147 participants
Children's Oncology Group
View Study Details
RecruitingOrange, CTNCT04068194

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

This phase I/II trial studies the best dose and side effects of peposertib and to see how well it works with avelumab and hypofractionated radiation therapy in treating patients with solid tumors and ...

103 participants
National Cancer Institute (NCI)
View Study Details
RecruitingOrange, CTNCT06620302

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

This phase I/II trial tests the safety, side effects and best dose of DT2216 in combination with irinotecan and how well it works in treating children, adolescents and young adults with solid tumors a...

81 participants
Children's Oncology Group
View Study Details
RecruitingOrange, CTNCT05038150

Study of SGN1 in Patients With Advanced Solid Tumor

Objectives:To assess the safety and tolerability followed by a dose expansion study to characterize safety, and preliminary efficacy of SGN1 in participants with refractory solid tumors. Study Ration...

70 participants
Guangzhou Sinogen Pharmaceutical Co., Ltd
View Study Details
RecruitingOrange, CTNCT04870944

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has c...

63 participants
Children's Oncology Group
View Study Details

About Advanced Solid Tumors Clinical Trials in Orange

Advanced solid tumors refer to cancers that have grown beyond the original site or spread to distant organs. Many clinical trials enroll patients with various types of advanced solid tumors to test novel therapies. These trials often investigate immunotherapy, targeted therapy, and combination approaches.

There are currently 9 advanced solid tumors clinical trials recruiting participants in Orange, CT. These studies are seeking a combined 5,096 participants. Research is being sponsored by Merck Sharp & Dohme LLC, Turning Point Therapeutics, Inc., D3 Bio (Wuxi) Co., Ltd and 4 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Advanced Solid Tumors Clinical Trials in Orange — FAQ

Are there advanced solid tumors clinical trials in Orange?

Yes, there are 9 advanced solid tumors clinical trials currently recruiting in Orange, CT. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Orange?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Orange research site will contact you about next steps.

Are clinical trials in Orange free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Orange studies also compensate for your time and travel.

What advanced solid tumors treatments are being tested?

The 9 active trials in Orange are testing new therapies including novel drugs, biologics, and treatment approaches for advanced solid tumors.

Data updated March 2, 2026 from ClinicalTrials.gov